Renal Cell Carcinoma
April 21, 2021
First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma
The ASCO Post
January 02, 2025
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
June 05, 2023
Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Dana-Farber
Advertisement
Recommendations
Advertisement